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1. Abstract 
Gaucher disease (GD) is the most common lysosomal storage disease worldwide. The 
incidence of the disease is significantly higher in certain ethnic groups, such as in 
Ashkenazi Jews. Mutation in the GBA1 gene results in a decreased catabolic enzymatic 
activity of the enzyme glucocerebrosidase which leads to the accumulation of 
glucocerebroside in various organs and their dysfunction. Other genetic mutations at 
different loci seem to modify the severity of the disease by unclear mechanisms.  GD is  
differentiated into three types. Currently, the common understanding of the disease 
suggests a spectrum of presentations, ranging from asymptomatic to extremely severe 
disease rather than three separate entities. Three types of classification of disease are 
in use, indicating severity and organ system affected in patients.Type 1, known as non-
neuropathic, mostly affects the bones, spleen, liver and bone marrow. Type 2 and 3, 
known as the neuropathic forms of the disease, differing in severity, age of diagnosis, 
rate of progression and life expectancy. GD2 usually manifests during infancy and has 
an accelerated progression the results in mortality during 2nd to 4th years of life. Type 3 
varies more in presentation and severity. The most common clinical findings in children 
with GD 1 are hepatosplenomegaly, anemia, and thrombocytopenia. Clinical findings 
that increase the suspicion for GD require a definitive diagnosis using 
glucocerebrosidase assay. Before initiation of treatment, a complete baseline 
assessment is performed to assess severity and to set goals for treatment. The specific 
treatment for GD in children is enzyme replacement therapy (ERT). This therapy was 
shown to lower morbidity and complication related to the disease. None of the 
neuropathic symptoms presenting in GD2 and GD3 seemed to benefit from ERT. These 
patients will benefit from ERT only in cases of visceral and bone involvement. The 
follow up of pediatric patients with GD is a lifelong journey that will require regular 
checks which are essential to assess the efficacy of the treatment and the need for 
modifications.  
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2. Sažetak 
Gaucherova bolest (GB) je najčešća lizosomska bolest nakupljanja u svijetu. Učestalost 
ove bolesti je znatno veća u nekim etničkim skupinama kao što su Židovi Aškenazi. 
Mutacija u genu GBA1 dovodi do smanjene kataboličke enzimske aktivnosti enzima 
glukocerebrozidaze koja dovodi do nakupljanja glukocerebrozida u različitim organima i 
rezultira njihovom disfunkcijom. Mutacije na drugim genskim lokusima, čini se, mijenjaju 
težinu bolesti putem nejasnih mehanizama. GB se obično dijeli na tri podvrste, ali 
trenutno razumijevanje bolesti je da se bolest ne sastoji od tri zasebna entiteta, već 
zapravo ima spektar prezentacija, od asimptomatskih do teških oblika bolesti. Tri 
podvrste bolesti se još uvijek često koriste kako bi se označilo koji su organski sustavi 
pogođeni u određenom pacijentu  i koliko teško. Tip 1, poznat kao ne-neuropatski, 
najčešće utječe na kosti, jetru, slezenu i koštanu srž. Tip 2 i 3 poznatiji su kao 
neuropatski oblici bolesti i međusobno se razlikuju po težini, dobi dijagnoze i očekivanoj 
duljini životnog vijeka. GB tip 2 se obično dijagnosticira tijekom prve dvije godine života, 
a smrt se događa od druge do četvrte godine života. Tip 3 ima varijabilniju kliničku sliku. 
Najčešći klinički nalazi kod djece s GB su hepatosplenomegalija, anemija i 
trombocitopenija. Klinički nalazi koji povećavaju sumnju na GB će zahtijevati konačnu 
dijagnozu mjerenjem aktivnosti glukocerebrozidaze. Prije započinjanja liječenja obavlja 
se cjelovita evaluacija kako bi se odredila ozbiljnost bolesti i kako bi se postavili ciljevi 
liječenja. GB se u djece liječi nadomjesnom enzimatskom terapijom (NET). Pokazalo se 
da ova terapija smanjuje morbiditet i komplikacije povezane s GB-om. Niti jedan od 
neuropatskih simptoma koji su bili prisutni u tipovima 2 i 3 GB nije se poboljšao s NET-
om. Bolesnici s ovim tipovima GB imat će koristi od NET-a samo u slučajevima kad su 
zahvaćene kosti i visceralni organi. Praćenje pedijatrijskih slučajeva s GB-om je 
cjeloživotno putovanje koje zahtijeva periodične provjere, potrebne kako bi se 
procijenila učinkovitost liječenja i potreba za izmjenama istog.  
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3. Introduction 
Gaucher's disease (GD) in one of the lysosomal storage diseases (LSD). GD is the 
commonest of these diseases worldwide. These diseases are a consequence of genetic 
mutations leading to a lack of or diminished catabolic enzymatic activity, subsequently 
leading to accumulation of metabolic products in variable organ systems and cells 
throughout the body. The enzyme involved in the development of GD is 
glucocerebrosidase (acid β-glucosidase, D-glucosyl-N-acylsphingosine glucohydrolase, 
or GCase). Latest registry reports indicate that GD becomes clinically symptomatic 
during the first 20 years of life, with the majority of cases reporting either laboratory or 
physical clinical findings preceding that. Due to the availability of treatment and 
management protocols, early diagnosis and treatment initiation will result in decreased 
morbidity and increase life expectancy in patients. The purpose of this paper is to 
provide an outline of contemporary data and knowledge about the pathophysiology of 
the disease, laboratory and clinical findings, current guidelines of management and 
follow up and to familiarize physicians with future lines of treatment. These tools can 
hopefully hasten the diagnosis and treatment of GD. 
 
4. Epidemiology 
GD annual incidence is approximately 1/40,000 to 1/60,000 in the general population. It 
should be taken into consideration that the disease incidence is highly dependent on 
ethnicity and consanguinity, evidenced by the significantly higher incidence of the 
disease (mostly type GD1) among Ashkenazi Jews in which the occurrence is 1/800 
[1,2]. Different types report different symptoms and affected areas and are grouped as 
follows: Type 1 (formerly known as non-neuropathic)  is the most common type and 
comprises 90-95% of patients. This type mostly affects the bones, liver, spleen and 
bone marrow. Type 2 and 3 are significantly less common in the general population and 
are encompassing only 5% of all patients (4% and 1% respectively) [3]. In addition to 
the Ashkenazi group, the largest single ethnic group represented, a further retrospective 
analysis performed in Sweden found a higher occurrence of GD3 than the worldwide 
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representation. The increased prevalence of GD3 in Sweden is a result specific 
mutation which is more prevalent in the province of Norrbotten in Sweden [4]. 
 
5. Genetic mechanism and pathogenesis  
As an autosomal recessive disease, GD is a result of reduced activity of the enzyme 
glucocerebrosidase, which breaks down the glycosphingolipid glucosylcerebroside to 
glucose and ceramide in the lysosomal compartment. The gene, GBA1, which codes for 
the enzyme, is located on the long arm of chromosome 1 (1q21). More than 300 
mutations have been identified so far [5]. The only known mutation that does not involve 
GBA1 gene that results in the development of GD (mostly GD 3) is a rare mutation of 
the protein saposin C. This protein is an activator of glucocerebrosidase enzyme [6]. 
The identification of these mutated genes was thought to lead to clear phenotype-
genotype correlation. Unfortunately, so far, there is only a limited number of specific 
mutations which provide valuable, accurate information about the predicted phenotype. 
The most known of these is N370S which results in GD type 1. Patients who inherited 
the N370S gene, whether they are homozygous (two alleles of N370S) or heterozygous 
with another mutated gene, will mostly develop type 1 disease. A rare and unique gene 
mutation is D409H mutation [5], resulting in the development of an extremely rare 
presentation that includes calcification of aortic and mitral valves, corneal opacities and 
hydrocephalus (Type 3C) [7].  
All genetic mutations will consequently lead to decreased activity of the enzyme 
glucocerebrosidase (GCas). The decreased enzymatic activity could be a result of both 
diminished activity of the enzyme or decreased production of it. Another process that 
leads to decreased lysosomal enzymatic activity is the defective transportation of the 
enzyme from the rough endoplasmic reticulum (RER) to its final destination in the 
lysosome. The abnormal transportation of the enzyme will lead to its aggregation in 
different cellular compartments (cytoplasm, RER) and premature breakdown by 
proteasomes [1,8]. 
Decreased lysosomal enzymatic activity leads to accumulation of the metabolite 
glucosylcerebroside in lysosomes. RBC and WBC are removed from the circulation by 
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the macrophages of the mononuclear phagocyte system on regular intervals. These 
cells contain a significant amount of glycosphingolipids, glucosylcerebroside being 
among these in their cell membranes. For this reason, macrophages are the cells most 
significantly affected by this lysosomal enzymatic deficiency. The accumulation of 
glucosylcerebroside in the lysosomes promotes the transformation of macrophages into 
Gaucher cells. These cells are described under the light microscope as enlarged cells 
having "crumpled tissue paper" appearance. Gaucher cells are thought to be the culprit 
of most pathological manifestations of the disease. These cells usually infiltrate the 
spleen, liver, and bone. Liver and spleen infiltration will result in hepatosplenomegaly. 
Bone infiltration by these cells will lead to the skeletal complications [9] (see clinical 
presentation). 
Neurological involvement is significantly less understood since glucosylcerebroside 
levels are low in the neural system in comparison to other organs involved. It is 
hypothesized that only cases of extremely low levels of enzymatic activity, such as 
those observed in type 2 and three diseases, will cause neuronal involvement [10]. 
Accumulation of glucosylcerebroside in macrophages promotes shifting of this 
metabolite toward an alternative metabolic path. This path will result in the increased 
formation of specific metabolites such as glucosylsphingosine. Glucosylsphingosine is 
undetectable in GD  patient without neurological manifestations and unaffected 
individuals but is elevated in  GD patients with neurological disease [11]. 
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Figure 1: Biochemical pathway leading to accumulation of glucocerebroside and 
glucosylsphingosine. Modified from Pastores et al. [18]. 
 
Furthermore, gene modifiers, genes that can modify or alter gene expression, probably 
lead to the broad spectrum of phenotypic presentation among patients with the same 
GBA1 mutation. A recent study performed on 15 inbred mouse strains that were 
injected with the same amount of glucocerebrosidase enzyme inhibitor, induced 
decreased enzymatic activity mimicking GD. The experimental sample showed 
significant genetic variance in the group. It allowed the researchers to investigate 
specific gene modifiers that modified the severity of disease presentation. The study 
resulted in identifying 17 putative modifier genes were identified, among which are 
NR2B and the B subunit of the NMDA Receptor. Treatment with NMDA antagonist 
prolonged the lifespan. The generalizability of the finding to human subjects is limited 
and pending on further investigation and clinical studies. [47]. 
 
 
6. Clinical presentations 
GD manifests profoundly different clinical presentations, ranging from a severe prenatal 
presentation which results in hydrops fetalis, to entirely asymptomatic patients. Current 
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consensus utilizes the three types, despite understanding that they no longer present 
distinct entities, but rather a spectrum of phenotypes. The tripartite classification is in 
common usage, illustrating the onset age, neural involvement and the rate of 
progression. 
6.1 GD type 1 
GD 1 (non-neuropathic) is the most common type globally [3]. It is distinguished from 
the other types of the disease by the lack of neurological symptoms. The spectrum of 
clinical presentation varies extensively, ranging from utterly asymptomatic patient to 
severely symptomatic patients presenting during early childhood. For many years it was 
considered a disease that manifests and becomes clinically symptomatic during 
adulthood. In fact, two-thirds of GD1 patients become clinically symptomatic during 
childhood and adolescence [12]. Description of the clinical presentation is done 
according to the most common symptoms and signs presenting from childhood to 
adolescence. What follows is a brief overview according to most common organ 
systems. 
Splenomegaly is observed in 95% of children diagnosed with the disease before the 
age of six. This finding is one of the earliest findings a physician should be aware of, 
and for this reason, it is suggested as the starting point of the algorithm for the 
diagnosis of GD in children (presented in the diagnosis section) [12]. Splenomegaly 
may lead to hypersplenism- a condition resulting in decreased numbers of RBC, 
platelets, and WBC. Spleen volume can reach up to 15 times the average volume in the 
same age group [13]. Splenomegaly can result in abdominal distention, pain and 
discomfort, early satiety and gastroesophageal reflux due to its increased size 
occupying the abdominal cavity leading to compression of adjacent structures. Two rare 
complications due to enlarged spleen size are splenic infarction (more common) and 
splenic rupture [14]. Both present as severe abdominal pain which requires immediate 
intervention [15,16]. The preferred imaging modality for estimating the extension of 
spleen enlargement is MRI [17]. In settings where MRI is unavailable ultrasonography is 
used, despite its limitations in accuracy.  
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Hepatomegaly– is recognized in more than 85% of children diagnosed with GD1 at 
time of diagnosis. The liver is enlarged to a lesser extent than spleen, usually ranges 
from 1.5-2.5 times more than average [13]. Hepatomegaly can lead to a similar physical 
presentation as splenomegaly due to its enlarged size. Hepatic infarction is a rare 
complication that can present as severe abdominal pain, similarly to splenic infarction 
and managed in the same manner [15,16]. 
Bone disease is probably the most debilitating consequence of GD1 and affects the 
quality of life to the most significant extent. The skeletal involvement is a slow and 
gradual process. Consequently, the extent of bone disease is found to correlate with the 
age of the patients (figure 3). Patients who are diagnosed later in life are found to have 
more clinical and radiological evidence of bone involvement than those diagnosed and 
treated earlier in life [13]. Bone involvement commonly affects the pelvis and lower 
limbs [4]. This can result in moderate lower extremity pain in children which on many 
instances is incorrectly diagnosed as typical growing pain [13]. This continued bone 
involvement results in radiological findings indicating bone disease in 81% of children at 
the time of diagnosis [13] (figure 3). MRI is the preferred modality to evaluate bone 
involvement such as bone infarction, avascular necrosis, marrow infiltration, lytic lesions 
and new fractures. One specific radiological finding is known as ‘Erlenmeyer flask 
deformity' refers to the narrowing of the diaphysis and the expansion of the metaphysis 
(figure 2). These are found in the lower part of the femur. This finding is common in 
children with GD1 but is not pathognomonic and may be detected in other diseases 
(Niemann-Pick, sickle cell disease, etc.) [14].  
 
 
 
 
Figure 2:  a. MRI showing marrow infiltration. b. X-ray showing Erlenmeyer flask 
deformity. Modified from Orvisky et al. [10]. 
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Figure 3: Percentage of children with specific bone findings at the time of 
diagnosis according to age. Modified from Kaplan et al. [13].  
Bone mineral density is usually decreased as a result of the bone disease and can 
result in pathological bone fracture. Bone crisis is a common presentation of bone 
involvement in children with GD (30%) [14]. In addition to severe pain, it is accompanied 
by edema and warmth in the affected area, leukocytosis, and low-grade fever. The 
mentioned symptoms can last up to 7-10 days. These symptoms can be accompanied 
by an imaging finding of elevated periosteum, mimicking the presentation of 
osteomyelitis (pseudo-osteomyelitis) [14,18]. 
Delayed growth and puberty are of particular interest in regards to the pediatric 
population. Growth retardation can be divided to severe growth retardation (less than 
the 5th percentile), and moderate (less than 25th percentile), it is recognized in 34% and 
28% of children at the time of diagnosis, respectively [13]. The degree of growth 
deceleration usually correlates with the severity of the disease. Puberty and sexual 
maturation are delayed in more than 60% of patients [17]. Both are consequences of 
the disease itself, shown by the improvement of these symptoms upon initiation of 
enzyme replacement therapy (ERT). An indirect effect of both growth and puberty delay 
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is emotional distress experienced by children that should also be addressed by 
physicians [19]. 
Cytopenia is a frequent finding in GD1 prior to initiation of treatment. 
Thrombocytopenia and anemia are a result of multiple factors such as hypersplenism, 
bone marrow infiltration and the direct effect of accumulated metabolites on 
hematopoiesis [20, 21]. Approximately 40% of children are found to have a certain 
degree of anemia or thrombocytopenia at the time of diagnosis. Decreased number of 
WBC (leukopenia) can also occur but to a lesser extent [13].  
Thrombocytopenia manifests as mucosal bleeding that can be observed during teeth 
brushing. It can additionally present as frequent and prolonged nosebleeds or excessive 
bleeding following trauma [18]. Bleeding disorders may also be due to platelet 
aggregation abnormalities and coagulation disorders. As a consequence, PT and PTT 
might be prolonged [22]. 
Anemia usually manifests as general fatigue, inability to play for prolonged periods of 
time or the lack of desire to participate in physical activity. 
Leukopenia is seldom severe enough to necessitate any intervention or to have any 
clear consequences. 
Hypergammaglobulinemia in children is commonly due to increased production of 
polyclonal antibodies. This usually resolves with the initiation of ERT [23].  
 
6.2 GD type 2 (acute neuropathic, infantile)  
GD 2 is the most severe form of the disease. It affects only 1% of individuals with GD 
[14]. It is characterized by visceral and neurological involvement but lack of bone 
involvement. Initial symptoms present most commonly around 6 months of age and in 
the vast majority before the age of 2. Visceral signs are similar to the ones described in 
GD1 and include hepatosplenomegaly and cytopenia. Neurological symptoms include: 
bulbar signs (stridor, swallowing impairment), hypertonicity (of the neck and trunk 
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known as opisthotonus, and of the jaw known as trismus). Oculomotor paralysis can 
also occur. Psychomotor development is substantially limited in these patients. Most 
patients suffering from GD 2 die by 2-4 years of age most commonly due to apnea and 
pulmonary complications [24]. Severe presentation of GD2 also known as perinatal or 
lethal form, presents with several unique findings. Skin findings include collodion skin 
abnormalities, referring to the bright, shiny and tight appearance of those newborns’ 
skin. The skin of these newborns is usually being shed during the first weeks of life and 
puts them at risk for dehydration due to fluid loss through the skin. Nonimmune hydrops 
fetalis could be another presentation of this severe form of the disease and result in 
death of the fetus or premature delivery [24].  
6.3 GD type 3 (juvenile or subacute or chronic) 
GD3 can present with bone involvement, similar to GD1, and with neurological 
involvement, similar to GD2, along with visceral involvement. Age of presentation is 
highly variable, most commonly during childhood but might also happen in infancy or  
adulthood. It usually follows a slow progressive course in comparison to the rapidly 
progressive course of type 2. Patients usually survive to 3rd and 4th decades of life [18]. 
Type 3 has wide range of presentation. On one side of the spectrum, patients can suffer 
from an isolated neurological finding such as horizontal ophthalmoplegia, whereas on 
the other side of the spectrum patients can suffer from more severe symptoms such as 
debilitating hypertonicity or frequent seizures. Neurological symptoms which are 
commonly observed in GD3 patients are myoclonic epilepsy, cerebellar ataxia and 
spasticity [18,25, 26]. GD patients can initially be considered to have GD1 type due to 
the lack or mild presentations of neurological symptoms. Therefore it is essential to 
perform focused periodic neurological examinations to patients presenting solely with 
visceral and bone involvement, in order to assess any changes that will lead to 
reclassification. The cardiovascular (3C) form is an extremely rare presentation of GD. It 
mostly presents during childhood in individuals which are homozygous for the D409H 
mutated allele. Common manifestations are mitral and aortic valve calcifications, 
splenomegaly, corneal opacities, supranuclear ophthalmoplegia and hydrocephalus 
[18]. 
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7. Diagnosis  
In many cases the diagnosis of GD is made years after initial symptoms which in type 1 
usually start during childhood and adolescence [13]. Due to the availability of treatment 
and with intention of prevention of irreversible consequences, timely diagnosis is of 
paramount importance. For this reason it is essential for physicians to diagnose a child 
with the disease as quickly as possible in order to prevent future irreversible 
consequences of the diseases. In the following section important diagnostic tests will be 
described as well as a proposed diagnosis algorithm in children [13]. 
Upon completion of the initial workup of a susceptible patient, further inquiry into 
detailed clinical and family history is necessitated. Susceptible ethnic groups are an 
addition factor for differential diagnosis. The most important of these ethnic groups are 
Ashkenazi Jews. The clinical history should include all  signs and symptoms previously 
described (see clinical presentation section). Signs for abdominal distention or pain, 
early satiety, loss of weight and fatigue. Any history of bleeding or bruising should be 
investigated while focusing on mucosal bleeding, such as bleeding during teeth 
brushing and epistaxis. Growth deceleration or failure to thrive are of particular interest 
in the pediatric population and could be one of the initial presenting symptoms in a 
slowly progressing disease. Musculoskeletal examination should be performed. This 
includes different radiological modalities such as x-rays, MRI or ultrasound. 
Neurological examination is critical in order to identify patients with GD2 and GD3. 
Blood work is an essential part of the initial workup and can demonstrate a decreased 
number of platelets, moderate anemia and on rare occasion leucopenia. 
7.1 Definitive diagnosis modalities  
Glucocerebrosidase  activity essay  
The diagnosis of GD, regardless of the type, is made by proving a decreased activity of 
the glucocerebrosidase enzyme. This is done by a fluorometric assay using the 
substrate 4-methylumbelliferyl-β-D-glucopyranoside to measure enzyme activity. The 
assay is done in different cells such as leukocytes, mononuclear or cultured fibroblasts 
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from a skin biopsy. Enzymatic activity in affected individuals is usually 0-15% in 
comparison to non-affected individuals [18].  
Genetic testing 
Genetic testing is used as an additional confirmatory test to glucocerebrosidase activity 
assay, for carrier screening and to a limited extent to correlate phenotype with 
genotype. A child diagnosed with the disease using glucocerebrosidase enzyme assay 
is commonly referred to genetic analysis test, which will determine the genotype of the 
child. An identified genotype is used for screening other relatives that could be carriers 
or still asymptomatic. The recognition of a specific genotype could provide information 
about the course of the disease. As described earlier the mutation N370S will result in 
GD1 in contrast to the L444P genotype which will mostly result in a more severe 
neurological disease [1,5]. 
Specific techniques are used to detect a genetic mutation in the GBA1 gene. The 
genetic analysis usually follows three steps of progression. The initial technique used is 
targeted analysis for pathogenic variants in a proband. This detects the most common 
variants which can change in prevalence among different populations. In Ashkenazi 
Jews, four variants are found in 90% of diagnosed patients. In comparison, these four 
genes are contributing only to 60% of GD patients in the general population [18]. In 
cases in which the mutation cannot be detected by the targeted analysis test, the 
subsequent step will be the utilization of the sequence analysis method. This technique 
will sequence the entire GBA1 gene and will identify small genetic deletions/insertions 
and missense, nonsense, and splice site variants. Approximately 99% of mutations will 
be detected by sequence analysis. Rarely sequence analysis is not able to detect small 
deletions and duplications in the gene, and on that rarity, it leads to the utilization of 
deletion/duplication analysis [18] (figure 4). 
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Figure 4: Suggested algorithm for genetic diagnosis of GD. Modified from 
Pastores et al. [18]. 
7.2 Bone marrow aspiration  
Bone marrow aspiration and its examination are not mandatory or essential for the 
diagnosis of GD. In most cases, it is performed due to the low number of platelets and 
RBC, or hepatosplenomegaly that can raise suspicion for hematological or malignant 
diseases. The bone marrow examination could provide valuable information when 
Gaucher cells are identified on microscopic examination. It is critical to acknowledge 
that neither the presence or the absence of these cells confirms or excludes the 
diagnosis of GD by itself. "Look-alike " pseudo-Gaucher cells are known to be found in 
other diseases such as hematologic malignancies [27,28], sickle cell disease [29] and 
different mycobacterial infections [30]. Due to the close resemblance of pseudo-
Gaucher to Gaucher cell, determination of clear differentiation is done with extra caution 
[31].  
7.3 Biomarkers in the diagnosis and follow up  
Several biomarkers are elevated in patients with GD. These are used to lead the 
algorithm towards glucocerebrosidase enzyme assay that will confirm the diagnosis(see 
diagnosis algorithm, Figure 5), or follow the response to treatment and predict 
prognosis. 
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Chitotriosidase is an enzyme produced in excessive amounts by Gaucher cells. It has 
been utilized as a biomarker for over two decades [32]. This biomarker is mostly used to 
follow the response to treatment. Chitotriosidase can also be used to a lesser extent as 
a prognostic factor, whereby high activity correlates with a worse prognosis. The main 
disadvantage of chitotriosidase is that approximately 6% of patients with GD can also 
have coexistent mutations in the enzyme’s gene, which in turn can lead to a complete 
(homozygous) or diminished (heterozygous) levels of it. Therefore, in these patients 
using this biomarker can be misleading. Chitotriosidase can also be elevated in other 
lysosomal storage diseases. These render the results and make them less reliable [33].  
CCL18 is a chemokine formed by different cells, most important being dendritic cells 
and macrophages [34]. Also, Gaucher cells can also produce high levels of this 
chemokine. Thus it can be found in high levels in patients' plasma. The levels of CCL18 
could be elevated in different diseases which result in chronic inflammation, as well as 
in allergic reactions [35]. High levels are usually indicative of worse prognosis [14]. 
Glucosylsphingosine is a relatively new biomarker detected which is considered to be 
superior to the previous two due to its reliability, specificity, and sensitivity but is still not 
widely used [18]. 
Elevated levels of ferritin are typically found in patients with GD (>85%) [36]. 
Two additional biomarkers which are less commonly used today due to the availability 
of better biomarkers are tartrate-resistant acid phosphatase (TRAP) and 
angiotensin-converting enzyme (ACE). Both are frequently elevated in GD Patients 
[37]. 
7.4 Screening of GD 
In some countries, glucocerebrosidase activity essay is being performed as part of 
national screening programs for detection of metabolic disease in newborns using a 
dried blood spot technique. This leads to early diagnosis and follow up of patients and 
early treatment initiation. This will consequently prevent the development of 
unnecessary complications [18]. 
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7.5 Diagnostic algorithm 
The most current and comprehensive diagnostic algorithm is the 2014 report by Italian 
experts, based on the International Collaborative Gaucher Group Registry (ICGG). 
Delete the sentence the algorithm is intended [39]. 
99% of children with GD under the age of 6 are found to have splenomegaly to a certain 
extent at the time of diagnosis and is the sole sign in 50% of those patients [39]. For 
that reason, it was chosen to be the starting point of the algorithm. Following detection 
of an enlarged spleen that could be a result of other diseases as well, a noninvasive, 
available and rapid blood test is the next step in the algorithm. Thrombocytopenia and 
anemia are found in 50% and 41% respectively at the time of diagnosis in children [39]. 
Next step is dependent on whether thrombocytopenia or anemia was detected in blood 
tests. If any of these was found, or if there is no other acceptable etiology for the 
enlarged spleen, the algorithm guides to tests which are more specific for GD. Blood 
Tests are evaluating levels of biomarkers such as TRAP, ACE, ferritin, CCL18, 
chitotriosidase, and glucosylsphingosine. An x-ray will also be performed during this 
step, evaluating for the presence of Erlenmeyer flask deformity which is found in 49% of 
children at the time of diagnosis [39]. Growth deceleration evaluation and assessment 
of ophthalmological abnormalities are being completed simultaneously. If none of the 
following criteria was detected bone marrow aspiration is being performed to evaluate 
for hematological, hemato-oncological and communicable diseases etiologies. 
Examination of bone marrow aspiration might detect Gaucher or pseudo-Gaucher cells. 
Finding of any of these cells and its evaluation should be done with respect to other 
findings on bone marrow aspiration. If any of the following criteria described is being 
detected, the risk of GD is significantly high and necessitates a confirmatory test of 
glucocerebrosidase activity essay [12] (figure 5). 
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Figure 5: Diagnostic algorithm. Modified from Di Rocco et al [12]. 
 
8. Treatment and management 
Management of a child diagnosed with GD starts instantaneously after diagnosis is 
made and confirmed by appropriate modalities. It follows a standard timeline that starts 
with diagnosis and followed by establishing a baseline of common parameters which will 
be closely monitored during treatment (figure 6). The next step after establishing 
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baseline parameters will be the initiation of treatment (mostly ERT, bone marrow 
transplantation is reserved for selected cases) in eligible patients. Subsequently, a close 
follow up is required to adjust treatment to individually treat symptomatic complications 
of the disease (bone crisis, anemia, etc.). 
 
 
Figure 6: Suggested timeline in the management of children with GD. 
Extensive and elaborated clinical work in combination with disease-oriented physical 
examination are essential after diagnosis has been established by enzyme assay or 
genetic testing. The findings can define the goals of treatment. 
Blood work 
Initial blood work is performed to evaluate the state of the patient. This should include 
full blood count (CBC), hepatic (AST, ALT) and renal function tests, iron, ferritin, vitamin 
D, vitamin B12 and specific biomarkers. Important biomarkers that should be checked 
are chitotriosidase, CCL18, glucosylsphingosine, TRAP and ACE [12,14]. All 
biomarkers should be measured to assess treatment options and its efficacy.  
Successful treatment will lead to a decrease in their levels [5]. An increased level of 
polyclonal immunoglobulins is a common finding in children and should be assessed as 
well. In addition, coagulation functions that include PT and PTT should be evaluated. 
Visceral assessment 
This includes assessment of liver and spleen sizes. These are assessed preferentially 
by MRI. In settings where MRI in unavailable, ultrasound can be used although it is not 
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as accurate. MRI requires the patient to stay still for a considerable period. This can 
present a challenge in the pediatric population. The use of sedatives should be 
considered in those cases [18]. 
Bone 
MRI of the spine and femur should be performed to assess bone involvement and 
infiltration. Each of the two types of MRI images (T1 and T2) are utilized to recognize 
and grade different bone pathologies. T1 weighted sequence is utilized to recognize and 
assess bone marrow infiltration. Assessment of bone marrow infiltration in children is 
significantly challenging. This is due to the presence of red bone marrow which does not 
exist in adults. As a result, MRI findings can be misleading if not interpreted by a skilled 
and experienced radiologist. T2 sequence images are done to identify bone infarctions. 
Bone density is appraised using total body DEXA (dual energy x-ray absorption). Wrist 
bones X-ray could be used in children to determine their bone age and asses growth 
delay [14]. 
Neurological  
Neurological examination of any child diagnosed GD is required. As noted earlier, the 
severity of neurological involvement could be utterly different. Children initially 
diagnosed with GD1 could suffer from GD3 since their neurological signs were not 
recognized or did not exist initially. More specifically, ophthalmological abnormalities 
can be the initial or the sole neurological abnormality in GD3. Children diagnosed with a 
neuropathic form of GD disease may require additional and more advanced 
neurological tests such as peripheral hearing measurement, brain MRI, EEG, and 
brainstem evoked responses [17]. 
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8.1 Application of treatment  
Treatment can be divided into specific treatment aimed to decrease the accumulation of 
glucosylcerebroside and to non-specific, aimed to provide symptomatic treatment of 
disease complications and manifestations. 
Specific treatment includes enzyme replacement therapy, SRT (substrate reducing 
therapy, not currently approved for the use in children) and bone marrow 
transplantation. Enzyme replacement therapy (ERT) has revolutionized the treatment 
for GD1 patients but at the same time did not improve or affect the neurological 
outcome of patients suffering from neurological pathologies such as in GD2 and GD3. 
Currently, many screening programs for the early detection of lysosomal storage 
diseases and other inherited metabolic disease are established. Therefore, more 
asymptomatic children are diagnosed at earlier ages. Currently, even though ERT is 
available in most developed countries, it is still relatively expensive. Due to the 
existence of asymptomatic and barely symptomatic patients, indications for initiation of 
ERT have been suggested (see table 1) [12]. 
Each of the following findings indicates initiation of ERT in an asymptomatic 
child. 
Diagnosed during first 20 years of life. 
Hemoglobin lower than 4.96 mmol/L 
Platelets number lower than 60,000 cells /ml 
WBC count lower than 3000 cells /ml 
Any symptomatic bone disease such as bone crisis or pain 
Any radiological or clinical evidence of bone disease even if the patient is 
asymptomatic 
Growth delay and diminished growth velocity 
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Pubertal onset delay 
Sibling with severe disease already treated with ERT 
Genotype associated with severe disease 
Height lower than 2 SD (below the 5th percentile) 
Decreased bone mineral density, Z score lower than 2 
Spleen or liver volume bigger than double the normal liver and spleen size 
*A patient that fulfills one or more of the described indications is eligible to ERT. 
Table 1. Indications for ERT initiation in symptomatic children. Modified from 
Kaplan et al [12]. 
 
The goal of specific treatment is to prevent and improve the patients’ symptoms. 
Specific goals have been described to guide treatment. These therapeutic goals are 
intended to provide doctors with tools for assessment of treatment efficiency and 
success (figure 7).                                                            
Figure 7. Therapeutic goals. Modified from Pastores et al. [18]. 
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8.1.1 Types of specific treatment  
Enzyme replacement therapy  
Enzyme replacement therapy is the standard of care for patients with GD 1 and GD 3 
with visceral and bone involvement. The goal of treatment is to overcome and 
compensate for the deficient activity of glucocerebrosidase enzyme by supplementing it 
artificially. Three ERT drugs are available and differ according to the cell type used for 
their production. All enzymes are chemically altered to expose their mannose residue. 
This alteration promotes their uptake by macrophages. Imiglucerase was the first ERT 
drug commercially available (1991) and is produced from Chinese hamster ovary cells. 
The other ERT currently available are Velaglucerase Alfa which is produced from 
human fibroblast-like cell lines, and Taliglucerase Alfa produced from a carrot cell line 
[14]. All ERTs are administered intravenously, and their dosing and regimen vary 
among different countries [18]. The current recommendation for severely affected 
children is a dose of 60 U/kg on a biweekly basis [7]. Moderately affected children 
should receive 30 U/kg on a biweekly basis. The treatment regimen can be changed in 
case the response is insufficient or if the response is too rapid to current treatment. A 
rapid response can indicate that a regimen with lower dosing can provide sufficient 
results. Most current regimens use doses of 20-120 U/kg dependent on the clinical 
response of the patient [12, 17]. 
ERT treatment in children commonly results in significant increase in platelets number, 
improvement of anemia, and in a decreased liver and spleen size. The most significant 
changes occur during the first year of starting treatment and continue to improve in the 
following seven years [13]. Children with GD who start treatment early in childhood do 
not experience delayed puberty compared to those who start treatment in late childhood 
[19]. Improvement in growth retardation was also evident during the first eight years of 
treatment with a median height improvement of 1.9 Z score unites [38]. ERT results in 
an increase of bone mass, cortical bone thickening, decrease in episodes of bone crisis 
[38], diminished bone pain [39] and decrease in the incidence of bone fractures [38]. All 
these beneficial effects on the skeletal system improve the quality of life and prevent 
future skeletal complications such as osteoarthritis, joint abnormalities, and 
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compression fractures. Levels of most biomarkers decrease after starting therapy [40, 
41]. Levels of immunoglobulins and ferritin usually normalize as well after treatment 
[42]. 
Side effects of ERT are generally well tolerated. An immune-mediated hypersensitivity 
reaction is the most common side effect. It presents as urticaria, gastrointestinal 
discomfort, and laryngeal irritations. These reactions are diminished in intensity by 
slowing down the rate of infusion or by prophylactic treatment with corticosteroids or 
antihistamines. [14] 
Bone marrow transplantation  
The goal of bone marrow transplantation is to replace the cells lacking glucocerebroside 
enzyme with healthy cells from a healthy donor. Bone marrow transplantation has high 
morbidity and mortality rates. As a result of the high effectiveness of ERT and the risks 
involved in bone marrow transplantation, it is no longer considered an appropriate 
treatment for the majority of patients with GD. This procedure might still be considered 
in specific patients such as those who do not respond to ERT treatment. Since ERT 
cannot cross the blood-brain barrier, theoretically this procedure can overcome this 
obstacle and improve the neurological symptoms of patients with GD. There is no 
current evidence showing that bone marrow transplantation offers any significant 
improvement of neurological symptoms in GD2 and 3 [43]. 
Substrate reduction therapy  
Substrate reducing therapy is aimed to decrease the synthesis of glucocerebroside and 
by that preventing its accumulation. It acts by inhibiting the enzyme glucosylcerebroside 
synthase. It offers the benefit of ease of use since it is taken orally. Thus it increases 
compliance rate. This drug is currently approved only for the treatment of mild to 
moderate GD1 in adults; hence it is discussed only briefly [24]. 
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8.1.2 Supportive care, non-specific treatment 
Non-specific treatment refers to any treatment that is intended to treat the patients’ 
symptoms and not the etiology of GD. The treatment of common symptoms and 
complications that were discussed in the clinical presentation section will be presented.  
The skeletal system is significantly affected in children with GD disease, both the bone 
marrow and the bone itself. Bone crisis occurs commonly in children with GD rather in 
adults. The treatment for these episodes is typically with analgesics and oral 
prednisolone [44]. 
ERT treatment typically results in an increase of hemoglobin number, platelets number 
and rapid decrease in spleen size [9]. In selected cases, when there is an insufficient 
response to treatment, blood transfusions can be considered to alleviate symptoms 
such as fatigue and bleeding, due to anemia and thrombocytopenia, respectively. 
Splenectomy used to be an optional treatment strategy aimed to solve the 
hematological abnormalities caused by hypersplenism, such as anemia and 
thrombocytopenia. Currently, this therapy is rarely utilized due to the effectiveness of 
ERT [6]. 
Respiratory complications are the most common cause of death in patients with GD2. 
The most common of these are laryngeal spasm and apnea [6,15]. Maintaining a patent 
airway in these patients using tracheostomy will prolong patients' lives. These children 
typically have a low quality of life, and the question of whether to perform tracheostomy 
or not is usually left to parents or legal guardians [45].   
Treating the neurological symptoms of patients with GD2 and GD3 is explicitly 
challenging, and does not follow standard guidelines. Patients suffering from spasticity 
and irritability can be treated with benzodiazepines. Parents should be familiarized with 
common side effects of benzodiazepines which include urinary retention, increased 
saliva production, constipation, general weakness and respiratory depression. 
Respiratory depression can further worsen respiratory abnormalities in these patients. 
Seizures are managed according to the specific seizure type. Phenobarbital is one of 
the older drugs for the treatment of epilepsy. It is commonly used for seizure control in 
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infants. Other drugs that are being used are phenytoin, levetiracetam, valproate. These 
might have significant side effects that should be considered and monitored during 
treatment [46]. 
8.2 Future treatments: overview  
Gene therapy  
Introducing a normal GBA1 gene into hematopoietic stem cells in vitro, followed by 
delivering them into GD patients was thought to treat the disease and at the same time 
decrease the morbidity and mortality involved in bone marrow transplantation. So far the 
clinical results of this treatment were unsatisfying [14,18]. 
Pharmacological chaperone therapy  
Chaperones are small molecules intended to promote proper trafficking, folding, and 
function of other molecules. Non Mutated proteins produced by the ER are normally 
recognized by endogenous chaperones, that bind to the protein and promote its proper 
folding and conformation. This in turn prevents aggregation of the protein in the ER and 
ensures proper trafficking of the protein to its goal destination (lysosomes) [14]. 
Abnormal/mutated proteins are not identified by endogenous chaperones leading to 
their aggregation in the ER and eventually to their degradation. This results in 
decreased enzymatic activity. Certain mutated proteins still possess residual catabolic 
activity. The goal of pharmacological chaperone therapy is to provide exogenous 
chaperone molecules that will bind to the mutated proteins that still possess residual 
catabolic activity. This in turn will promote their trafficking to lysosomes and will improve 
the enzymatic activity in patients. The relatively small size of chaperone molecules can 
aid in the passage of the blood-brain barrier and might provide benefit in the treatment 
of the neurological symptoms of GD2 and GD3 patients. Ambroxol, originally a 
secretolytic therapy, was identified by FDA (Food and Drug Administration) as a 
potential chaperone of the glucocerebrosidase enzyme. It is the most investigated and 
tested PCT for GD [49]. Treatment of GD with ambroxol was tested in multiple trials, 
none of which is a randomized control trial with a large amount GD patients. In studies 
that were performed on cultured fibroblasts from GD patients, the results had shown an 
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increase in the enzymatic activity levels of glucocerebrosidase after treatment with 
ambroxol [50,51]. A trial performed by treating healthy non-human primates with a dose 
of 100 mg/day of ambroxol had shown an increase in the levels of glucocerebrosidase 
activity in their brains [52]. Treatment trials on people are extremely challenging due to 
low prevalence of the disease. A trial performed in Israel on 12 patients with GD1 who 
were not treated with ERT, treated  these patients with a dose of 75 mg/day for 6 
months had shown positive results, where no patient exhibited exacerbation of the 
disease and 3 patients exhibited an improvement of their disease. One of the most 
significant trials that was performed in Japan on five patients with GD3 with neurological 
symptoms including myoclonus, seizure and pupillary reflex abnormalities. These 
patients were treated with high dose of ambroxol 25 mg/kg/day. High dose therapy was  
based on the fact that none of the prior trials had shown any significant toxicity of 
ambroxol. Patients responded to treatment and had a significant improvement of all 3 
symptoms mentioned previously. Levels of glucosylsphingosine levels in cerebrospinal 
fluid were decreased in comparison to values measured before treatment initiation, 
indicating significant passage of the drug through the blood-brain barrier [53]. Treatment 
efficacy with ambroxol in all trails was found to differ according to the specific mutations 
affecting the patients. Certain mutations were found to be more responsive to treatment 
than others [50, 51]. Dosing regimen will need to be further investigated even though 
there is no evidence of severe toxicities with the use of ambroxol that will limit the 
dosing regimen.  
8.3 Follow-up  
Follow-up of GD patients is a crucial aspect of their management. A proper well 
organized follow up will allow the treating physician to gain valuable information about 
the effectiveness of treatment and will allow him/her to tailor the treatment to individual 
patients (The current follow up guidelines are presented in figure 8). 
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*Significant exacerbation or dose modification should be followed with complete 
physical examination including height and body mass, measurement of hemoglobin, 
platelets, PT, PTT, and biomarkers. 
Figure 8: Follow-up strategy. Modified from Kaplan et al [17].  
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9. Discussion 
Our ability to diagnose GD early in the course of the disease or even earlier with the 
help of national screening programs, combined with the available ERT treatment, allows 
us to provide adequate treatment. The advancement in the understanding of the genetic 
factors underlying disease presentation including gene modifiers will hopefully 
encourage further investigation of this aspect. This may allow us to understand the 
pathophysiology of different GD types and to establish a more complete genotype, 
including identifying different gene modifiers. This, in turn, will help us achieve a better 
genotype-phenotype correlation. Furthermore, this may offer new targets for therapy in 
patients [48]. Even though significant advancement and improvement in the 
management of patients were documented during the last two decades, this is mostly 
isolated to GD1. We are still not able to provide children suffering from type 2 and 3 with 
appropriate and effective therapy. Different approaches were tried including ERT, gene 
therapy, and bone marrow transplantation. All seemed to be ineffective. Since 
management of GD1 is well established and accepted, the next step will hopefully be to 
provide GD2 and 3 with treatment that will provide a significant improvement in patients' 
life expectancy and quality. 
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